NIH Showcases BioSensics' Efforts in Advancing Clinical Trial Technologies and Facilitating Stroke Rehabilitation

BioSensics has been at the forefront of developing wearable-based technologies for healthcare and medical applications since its inception in 2007. Our work includes:

1. Creation of a groundbreaking fall detection technology that has not only transformed the medical alert sector but is also being used in numerous clinical trials to monitor falls. 

2. Release of first FDA-listed wearable devices designed for instrumented gait and balance assessments in 2013, which have been utilized in over 25 clinical trials for measuring the secondary and/or primary endpoints.

3. Development of PAMSys technology for precision actigraphy, enabling the measurement of over 40 independent parameters of physical activity and posture. 

We are delighted to have received recognition and acknowledgment from both the National Institute on Aging (NIA) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) last month, as they highlighted and presented BioSensics' efforts in advancing wearable-based technologies.

The NIA article highlights our leading wearable and digital health technologies for clinical trials that enable remote measures, at-home monitoring, and robust hybrid trial designs, in a way never possible before. The article emphasizes the role of our technologies in evaluating the effectiveness of drugs, as well as tracking disease progression.

The NICHD article showcased our work on developing an interventional wearable device for stroke recovery, called StrokeWear. The project is in collaboration with Dr. Paolo Bonato, PhD, Director of the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital, and Dr. Julie J. Keysor, PT, PhD, Director of the Behavior, Abilities and Technology Lab (B-ABLE) at MGH Institute of Health Professions. StrokeWear utilizes a patented wrist-worn sensor developed by BioSensics to track movement and function of both affected and non-affected arms of stroke survivors. It incorporates real-time haptic feedback to motivate users and help them achieve their recovery objectives. The efficacy of StrokeWear in facilitating stroke recovery is being studied in a Phase II clinical trial supported by a $3M grant award from the NICHD to BioSensics. 

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials and research, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that offers comprehensive end-to-end solutions and services for the acquisition of digital measures and biomarkers in clinical trials and research. BioSensics designs and validates all elements of its solutions, including wearable sensors, software, and algorithms. Our experienced research team extends complete scientific and technical consultation services, such as study design and protocol development, in addition to statistical analysis. Furthermore, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

BioSensics has received over $50M in research and development program support from the U.S. National Institute of Health (NIH). In 2022, BioSensics was chosen by NIH to create remote measurement technologies for use in clinical trials involving people with rare diseases.